Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997775 | 0.86 | TDP1 (0.47) | TDP1TSHRPOLBALDH1A1 | |
| SCHEMBL17929078 | 0.79 | SMN1; SMN2 (0.46) | TSHRPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL14118736 | 0.79 | BCHE (0.46) | TSHRPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL3033446 | 0.78 | KCNH2 (0.44) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10769406 | 0.77 | TDP1 (0.41) | TDP1TSHRMEN1KMT2ACYP2C9 | |
| SCHEMBL585331 | 0.77 | TSHR (0.47) | TSHRPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL11808863 | 0.75 | TDP1 (0.50) | TDP1TSHRPOLBMEN1KMT2A | |
| SCHEMBL13626178 | 0.75 | TSHR (0.46) | TSHRPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL820953 | 0.75 | TSHR (0.46) | TSHRPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL4722884 | 0.74 | TSHR (0.41) | TDP1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | PHARMACIA ITALIA S.P.A. (IT) | 2004-10-14 | — | — | US | disclosed |
| EP-1406889-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003006447-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | PHARMACIA ITALIA SPA (IT) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | TCF4, TCF7, TCF7L2 | TDP1 3444/4885TSHR 3122/4885POLB 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.